A Phase 1 Study of 177Lu-PSMA-617 in People With Gliomas

Full Title

LU-TARGET: A Phase 1 Study of Lutetium-177-PSMA-617 Adjuvant Radiotherapy for IDH wild type Gliomas Expressing PSMA following Standard Treatment

Purpose

Researchers want to learn if the radiopharmaceutical therapy 177Lu-PSMA-617 is a safe treatment for people with glioma. Radiopharmaceutical therapy delivers radiation directly into a tumor to destroy cancer cells.

The people in this study have glioma with normal IDH genes. They have also already received external beam radiation therapy. The types of glioma to be treated include:

• Diffuse astrocytoma
• Glioblastoma
• Diffuse midline glioma
• Diffuse hemispheric glioma
• Diffuse pediatric-type high-grade glioma

If you take part in this study, you will get 177Lu-PSMA-617 delivered intravenously (by vein). You will also take temozolomide, a standard treatment for your cancer, orally (by mouth). Your care team will explain the treatment schedule to you.

Who Can Join

To join this study, there are a few conditions. You must:

• Have glioma that has normal IDH genes.
• Have finished standard therapy, including radiation therapy.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Brandon Imber’s office at 631-212-6346.